IDEXX Laboratories, Inc. (IDXX) All Metrics
IDXX Valuation Metrics
IDXX Stock Price Metrics
IDXX Dividend Metrics
IDXX Growth Rate Metrics
IDXX Discounted Cash Flow Metrics
| Fair Value Price | $177.89 |
| Margin of Safety | (69.27%) |
IDXX Revenue Metrics
IDXX PE Ratio Metrics
| PE Ratio | 42.69 |
| PE Ratio Avg TTM | 50.31 |
| PE Ratio Avg 3Y | 48.97 |
| Current VS TTM Avg | -15.14% |
| Current VS 3Y Avg | -12.83% |
| Current VS 5Y Avg | -20.27% |
IDXX PS Ratio Metrics
| PS Ratio | 10.50 |
| PS Ratio Avg TTM | 12.11 |
| PS Ratio Avg 3Y | 11.29 |
| Current VS TTM Avg | -13.33% |
| Current VS 3Y Avg | -6.99% |
| Current VS 5Y Avg | -13.42% |
IDXX PB Ratio Metrics
| PB Ratio | 30.01 |
| PB Ratio Avg TTM | 32.95 |
| PB Ratio Avg 3Y | 30.73 |
| Current VS TTM Avg | -8.92% |
| Current VS 3Y Avg | -2.35% |
| Current VS 5Y Avg | -33.67% |
IDXX Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 43.25 |
| PFCF Ratio Avg TTM | 55.35 |
| PFCF Ratio Avg 3Y | 55.86 |
| Current VS TTM Avg | -21.86% |
| Current VS 3Y Avg | -22.57% |
| Current VS 5Y Avg | -32.97% |
IDXX Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.67 |
| Debt/Equity Ratio Avg TTM | 0.65 |
| Debt/Equity Ratio Avg 3Y | 1.10 |
| Current VS TTM Avg | +3.88% |
| Current VS 3Y Avg | -39.37% |
| Current VS 5Y Avg | -46.40% |
IDXX PEG Ratio Metrics
| PEG Ratio | 2.30 |
| PEG Ratio Avg TTM | 2.30 |
| PEG Ratio Avg 3Y | 2.30 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
IDXX FCF Yield
| FCF Yield | 2.31% |
| FCF Yield Avg TTM | 1.86% |
| FCF Yield Avg 3Y | 1.86% |
| Current VS TTM Avg | +24.27% |
| Current VS 3Y Avg | +24.23% |
| Current VS 5Y Avg | +39.93% |
IDXX Earnings Yield
| Earnings Yield | 2.34% |
| Earnings Yield Avg TTM | 2.01% |
| Earnings Yield Avg 3Y | 2.07% |
| Current VS TTM Avg | +16.42% |
| Current VS 3Y Avg | +12.86% |
| Current VS 5Y Avg | +20.76% |
IDXX EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 33.84 |
| Ev/Ebit Ratio Avg TTM | 39.79 |
| Ev/Ebit Ratio Avg 3Y | 38.50 |
| Current VS TTM Avg | -14.95% |
| Current VS 3Y Avg | -12.11% |
| Current VS 5Y Avg | -21.03% |
IDXX EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 31.30 |
| Ev/Ebitda Ratio Avg TTM | 35.76 |
| Ev/Ebitda Ratio Avg 3Y | 34.47 |
| Current VS TTM Avg | -12.47% |
| Current VS 3Y Avg | -9.19% |
| Current VS 5Y Avg | -18.23% |
IDXX EV/Assets Ratio Metrics
| Ev/Assets Ratio | 14.05 |
| Ev/Assets Ratio Avg TTM | 15.32 |
| Ev/Assets Ratio Avg 3Y | 13.69 |
| Current VS TTM Avg | -8.29% |
| Current VS 3Y Avg | +2.62% |
| Current VS 5Y Avg | -7.46% |
IDXX EV/Sales Ratio Metrics
| Ev/Sales Ratio | 10.70 |
| Ev/Sales Ratio Avg TTM | 12.34 |
| Ev/Sales Ratio Avg 3Y | 11.51 |
| Current VS TTM Avg | -13.30% |
| Current VS 3Y Avg | -7.02% |
| Current VS 5Y Avg | -13.65% |
IDXX Current Ratio Metrics
| Current Ratio | 1.17 |
| Current Ratio Avg TTM | 1.24 |
| Current Ratio Avg 3Y | 1.23 |
| Current VS TTM Avg | -5.65% |
| Current VS 3Y Avg | -5.26% |
| Current VS 5Y Avg | -12.36% |
IDXX Quick Ratio Metrics
| Quick Ratio | 0.84 |
| Quick Ratio Avg TTM | 0.90 |
| Quick Ratio Avg 3Y | 0.89 |
| Current VS TTM Avg | -6.15% |
| Current VS 3Y Avg | -5.35% |
| Current VS 5Y Avg | -14.72% |
IDXX ROIC Metrics
| ROIC | 40.27% |
| ROIC Avg 3Y | 34.89% |
| ROIC Avg 5Y | 35.94% |
| Current VS 3Y Avg | +15.43% |
| Current VS 5Y Avg | +12.06% |
| Current VS 10Y Avg | +29.88% |
IDXX Return on Assets Metrics
| ROA | 31.62 |
| ROA Avg TTM | 29.29 |
| ROA Avg 3Y | 27.30 |
| Current VS TTM Avg | +7.95% |
| Current VS 3Y Avg | +15.80% |
| Current VS 5Y Avg | +14.89% |
IDXX Return on Equity Metrics
| ROE | 65.99 |
| ROE Avg TTM | 60.82 |
| ROE Avg 3Y | 72.53 |
| Current VS TTM Avg | +8.50% |
| Current VS 3Y Avg | -9.02% |
| Current VS 5Y Avg | -19.21% |
IDXX Net Profit Margin Metrics
| Net Profit Margin | 24.62% |
| Net Profit Margin Avg TTM | 23.70% |
| Net Profit Margin Avg 3Y | 22.66% |
| Current VS TTM Avg | +3.88% |
| Current VS 3Y Avg | +8.64% |
| Current VS 5Y Avg | +9.17% |
Last Updated: Tuesday, June 9, 2026
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky